Watson Pharmaceuticals Inc. (WPI) Stock Research, Analysis & News

Quick Analysis on Watson Pharmaceuticals Inc. (WPI) Stock as of November 22, 2018

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Watson Pharmaceuticals Inc. (WPI) Stock below)

Watson Pharmaceuticals Inc. (WPI) Stock Profile Summary

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacturing, marketing, sale, and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health in the United States and internationally. The company offers its products for therapeutic categories, such as central nervous system, hormones and synthetic substitutes, cardiovascular, nephrology, and gastrointestinal. It operates in three segments: Global Generic, Global Brand, and Distribution. The Global Generic segment develops, manufactures, markets, sells, and distributes generic products, as well as distributes generic versions of third parties brand products. This segment offers various dosage forms, such as oral solids, transdermals, injectables, inhalation products, and transmucosals for indications, including pregnancy prevention, pain management, depression, hypertension, and smoking cessation. The Global Brand segment includes its promoted urology products, such as Rapaflo, Gelnique, and Trelstar; and various non-promoted products. The Distribution segment distributes generic and certain select brand pharmaceutical products manufactured by third parties, as well as by the company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians offices. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. It has a development and license agreement with Natco Pharma Limited to develop and commercialize lenalidomide tablets. Watson Pharmaceuticals was founded in 1983 and is based in Corona, California.

Watson Pharmaceuticals Inc. (WPI) Stock Key Statistics Research and Analysis as of November 22, 2018

Watson Pharmaceuticals Inc. (WPI) Stock Competitor Research and Analysis

Mylan, Inc. (MYL)Novartis AG (NVS)
Teva Pharmaceutical Industries Limited (TEVA)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
King Pharmaceuticals Inc. (KG)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)

Stock Research on Watson Pharmaceuticals Inc. (WPI)

Latest Market News on Watson Pharmaceuticals Inc. (WPI)


Click here to find the latest news on Watson Pharmaceuticals Inc. (WPI)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Mylan, Inc. (MYL)
Novartis AG (NVS)
Teva Pharmaceutical Industries Limited (TEVA)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
King Pharmaceuticals Inc. (KG)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)